Search research articles
Contact Us
Filters
Showing results (81-90 of 94) with videos related to
Page
of 10
Sort By:
Nature Communications
|
May 13, 2025
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 29, 2019
Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study
Nishi Suryavanshi, Matthew Murrill, Amita Gupta, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 4, 2019
Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease
Amita Gupta, Susan Swindells, Soyeon Kim, et al.
The Lancet. Infectious Diseases
|
January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials
Ekaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
Gates Open Research
|
March 13, 2018
Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
Ray Y Chen, Laura E Via, Lori E Dodd, et al.
The Lancet. Infectious Diseases
|
May 20, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Muge Cevik, Lindsay C Thompson, Caryn Upton, et al.
The Lancet. Infectious Diseases
|
March 8, 2025
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial
Álvaro H Borges, Marisa Russell, Dereck Tait, et al.
The Journal of Infectious Diseases
|
July 10, 2020
Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial
Tomas G Neilan, Kim-Lien Nguyen, Vlad G Zaha, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 94) with videos related to
Sort By:
Page
of 10
Nature Communications
|
May 13, 2025
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 29, 2019
Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study
Nishi Suryavanshi, Matthew Murrill, Amita Gupta, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 4, 2019
Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease
Amita Gupta, Susan Swindells, Soyeon Kim, et al.
The Lancet. Infectious Diseases
|
January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials
Ekaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
Gates Open Research
|
March 13, 2018
Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
Ray Y Chen, Laura E Via, Lori E Dodd, et al.
The Lancet. Infectious Diseases
|
May 20, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Muge Cevik, Lindsay C Thompson, Caryn Upton, et al.
The Lancet. Infectious Diseases
|
March 8, 2025
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial
Álvaro H Borges, Marisa Russell, Dereck Tait, et al.
The Journal of Infectious Diseases
|
July 10, 2020
Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial
Tomas G Neilan, Kim-Lien Nguyen, Vlad G Zaha, et al.
Page
of 10